Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide plus low-dose dexamethasone versus melphalan + prednisone + thalidomide in previously untreated multiple myeloma
2007-004823-39Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Feb 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lenalidomide, dexamethasone, melphalan, prednisone and thalidomide in multiple myeloma (MM) (3 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-free survival. Started Feb 2008; status: completed.
02
Drugs
lenalidomidedexamethasonemelphalanprednisonethalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2007-004823-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004823-39.